Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel Buys 4,000 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel purchased 4,000 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was acquired at an average price of $26.94 per share, for a total transaction of $107,760.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $107,760. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Anja Manuel also recently made the following trade(s):

• On Thursday, November 14th, Anja Manuel acquired 1,000 shares of Hims & Hers Health stock. The stock was bought at an average price of $24.50 per share, with a total value of $24,500.00.

Hims & Hers Health Stock Down 4.4 %

NYSE HIMS traded down $0.92 during trading on Friday, hitting $19.93. 9,936,868 shares of the stock traded hands, compared to its average volume of 9,157,209. The company has a market capitalization of $4.28 billion, a P/E ratio of 47.38 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $7.40 and a 12-month high of $30.44. The firm has a 50-day simple moving average of $19.64 and a 200-day simple moving average of $18.78.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the business earned ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HIMS. Truist Financial boosted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Piper Sandler restated a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating in a report on Thursday. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Finally, TD Cowen increased their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $21.21.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the period. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $111,000. Finally, Amalgamated Bank boosted its holdings in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.